Physician profile
Dylan Jackson Dick
NPI 1881216729
$4,182.46
in general payments reported to CMS, 2019-2025
31 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,216 · 2022: $912 · 2023: $614 · 2024: $263 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009 · Education: $45.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.50 |
| Education | $45.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $713.89 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $646.44 | 2021-2022 | |
| Abbvie INC. | $568.31 | 2021-2025 | |
| Novo Nordisk INC | $272.29 | 2021-2022 | |
| Lilly USA, LLC | $246.41 | 2021-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $236.34 | 2021-2022 | |
| Esperion Therapeutics, INC. | $232.02 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $187.14 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $157.16 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $124.45 | 2022 | |
| Pfizer INC. | $114.49 | 2021-2025 | |
| Sanofi Pasteur INC. | $107.33 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.27 | 2021-2022 | |
| Grifols USA, LLC | $70.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $67.42 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $63.91 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $34.79 | 2021-2022 | |
| Amarin Pharma, INC. | $31.56 | 2021 | |
| Redhill Biopharma INC. | $30.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.14 | 2022 | |
| Astellas Pharma US INC | $19.77 | 2021 | |
| Horizon Therapeutics Plc | $17.26 | 2022 | |
| Bardy Diagnostics, INC. | $16.89 | 2021 | |
| Inogen, INC. | $16.00 | 2022 | |
| Eisai INC. | $15.73 | 2021 | |
| Shield Therapeutics INC | $15.25 | 2023 | Accrufer |
| Sunovion Pharmaceuticals INC. | $15.09 | 2021 | |
| Uswm, LLC | $14.96 | 2021 | |
| Alkermes, INC. | $14.28 | 2021 | |
| Indivior INC. | $13.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Dick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.